Biogen

Biogen logo
🇺🇸United States
Ownership
Private
Established
1978-01-01
Employees
7.5K
Market Cap
$29.6B
Website
https://www.biogen.com
Introduction

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

First Posted Date
2010-01-18
Last Posted Date
2018-11-09
Lead Sponsor
Biogen
Target Recruit Count
410
Registration Number
NCT01051349
Locations
🇬🇧

Research Site, Stoke-on-Trent, United Kingdom

BIIB014 Cardiovascular Monitoring Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-12-18
Last Posted Date
2010-06-22
Lead Sponsor
Biogen
Target Recruit Count
24
Registration Number
NCT01035515
Locations
🇺🇸

Quintiles Inc, Overland Park, Kansas, United States

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-11-20
Last Posted Date
2023-08-23
Lead Sponsor
Biogen
Target Recruit Count
28
Registration Number
NCT01017666
Locations
🇬🇧

InCROM Clinical Research Unit, London, United Kingdom

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

First Posted Date
2009-11-20
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
20
Registration Number
NCT01017198
Locations
🇺🇸

Reseach Facility, San Antonio, Texas, United States

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-10-29
Last Posted Date
2015-10-02
Lead Sponsor
Biogen
Target Recruit Count
54
Registration Number
NCT01004081
Locations
🇷🇺

Research Site, St. Petersburg, Russian Federation

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

First Posted Date
2009-09-02
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
18
Registration Number
NCT00970580
Locations
🇺🇸

Resesarch Site, Denver, Colorado, United States

Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects

First Posted Date
2009-08-24
Last Posted Date
2017-10-26
Lead Sponsor
Biogen
Target Recruit Count
16
Registration Number
NCT00964288

Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-08-19
Last Posted Date
2014-10-28
Lead Sponsor
Biogen
Target Recruit Count
48
Registration Number
NCT00961766
Locations
🇦🇺

Research Site, Adelaide, South Australia, Australia

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-08-11
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
40
Registration Number
NCT00956436
Locations
🇬🇧

Resesarch Site, Edgbaston, Birmingham, United Kingdom

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-08-10
Last Posted Date
2017-10-16
Lead Sponsor
Biogen
Target Recruit Count
60
Registration Number
NCT00955396
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath